Ana L. Granados-Ortega

Jaen, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.

Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC.

Journal: JTO clinical and research reports

Published: August 11, 2025

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 17, 2025

Defining long-term survivors in metastatic lung cancer: insights from a Delphi study in Spain.

Defining long-term survivors in metastatic lung cancer: insights from a Delphi study in Spain.

Journal: Frontiers in oncology

Published: December 16, 2024

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 06, 2024

Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings.

Clinical outcomes and mortality in patients with atrial fibrillation and recently diagnosed lung cancer in oncology outpatient settings.

Journal: Current problems in cardiology

Published: November 24, 2023

Metabolomics signature as a survival predictor in patients with resectable colorectal liver metastasis.

Metabolomics signature as a survival predictor in patients with resectable colorectal liver metastasis.

Journal: Clinical and translational medicine

Published: September 22, 2023

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.

Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial.

Journal: Nature communications

Published: March 03, 2023

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 07, 2022

Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.

Predicting dynamic response to neoadjuvant chemotherapy in breast cancer: a novel metabolomics approach.

Journal: Molecular oncology

Published: October 29, 2021

"High Tumor Burden" in Metastatic Non-Small Cell Lung Cancer: Defining the Concept.

"High Tumor Burden" in Metastatic Non-Small Cell Lung Cancer: Defining the Concept.

Journal: Cancer management and research

Published: February 23, 2021

Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.

Early use of tocilizumab in patients with severe pneumonia secondary to severe acute respiratory syndrome coronavirus 2 infection and poor prognostic criteria: Impact on mortality rate and intensive care unit admission.

Journal: Medicine

Published: December 26, 2020

Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.

Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer.

Journal: Cancers

Published: December 07, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026